CN1857498A - Medicine for treating gynecopathy and its preparing method - Google Patents
Medicine for treating gynecopathy and its preparing method Download PDFInfo
- Publication number
- CN1857498A CN1857498A CNA2006100419383A CN200610041938A CN1857498A CN 1857498 A CN1857498 A CN 1857498A CN A2006100419383 A CNA2006100419383 A CN A2006100419383A CN 200610041938 A CN200610041938 A CN 200610041938A CN 1857498 A CN1857498 A CN 1857498A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- standby
- mesh sieves
- vacuum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 229940079593 drug Drugs 0.000 title claims description 8
- 238000000034 method Methods 0.000 title description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 51
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 27
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 18
- 241000628997 Flos Species 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- 239000012535 impurity Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 10
- 238000001704 evaporation Methods 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 239000012567 medical material Substances 0.000 claims description 9
- 239000002994 raw material Substances 0.000 claims description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000019634 flavors Nutrition 0.000 claims description 6
- 239000008188 pellet Substances 0.000 claims description 6
- 239000007779 soft material Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 239000007938 effervescent tablet Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 3
- 238000007598 dipping method Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 150000002333 glycines Chemical class 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 28
- 206010047799 Vulvovaginitis trichomonal Diseases 0.000 abstract description 13
- 206010046914 Vaginal infection Diseases 0.000 abstract description 9
- 208000004926 Bacterial Vaginosis Diseases 0.000 abstract description 7
- 230000002147 killing effect Effects 0.000 abstract description 7
- 208000003251 Pruritus Diseases 0.000 abstract description 4
- 230000008961 swelling Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 230000007803 itching Effects 0.000 abstract description 2
- 244000045947 parasite Species 0.000 abstract description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 abstract 1
- 244000035851 Chrysanthemum leucanthemum Species 0.000 abstract 1
- 241000972673 Phellodendron amurense Species 0.000 abstract 1
- 201000008100 Vaginitis Diseases 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 18
- 239000008921 jie er yin Substances 0.000 description 17
- 210000001215 vagina Anatomy 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 229960000282 metronidazole Drugs 0.000 description 6
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical group CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010042343 Subcutaneous abscess Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 229940095731 candida albicans Drugs 0.000 description 3
- IDWJWYPAJJDASX-GKXBZDASSA-N hachimycin Chemical compound O1C(=O)CC(=O)CC(O)CC(O)CCCC(O)CC(O)CC(O2)(O)CC(O)C(C(O)=O)C2CC(OC2C(C(N)C(O)C(C)O2)O)\C=C/C=C\C=C\C=C/C=C\C=C\C=C\C(C)C1C(C)CCC(O)CC(=O)C1=CC=C(N)C=C1 IDWJWYPAJJDASX-GKXBZDASSA-N 0.000 description 3
- 229960003372 hachimycin Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- SRAGSPNJULICDG-UHFFFAOYSA-N 1-[4-(5-nitro-1,3-thiazol-2-yl)piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=NC=C([N+]([O-])=O)S1 SRAGSPNJULICDG-UHFFFAOYSA-N 0.000 description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 2
- WWXBHTZSYYGCSG-UHFFFAOYSA-N [4-(carbamoylamino)phenyl]arsonic acid Chemical compound NC(=O)NC1=CC=C([As](O)(O)=O)C=C1 WWXBHTZSYYGCSG-UHFFFAOYSA-N 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 229950000776 carbarsone Drugs 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229960003913 econazole Drugs 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960004130 itraconazole Drugs 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960005053 tinidazole Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XWBADQOPXPRKBX-FMIVXFBMSA-N 1-n,1-n-diethyl-4-n-[6-methoxy-2-[(e)-2-(4-nitrophenyl)ethenyl]quinolin-4-yl]pentane-1,4-diamine Chemical compound N=1C2=CC=C(OC)C=C2C(NC(C)CCCN(CC)CC)=CC=1\C=C\C1=CC=C([N+]([O-])=O)C=C1 XWBADQOPXPRKBX-FMIVXFBMSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical class ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- -1 ace-tarsoni Chemical compound 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003716 antitrichomonal agent Substances 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000001586 eradicative effect Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 229960001660 histamine phosphate Drugs 0.000 description 1
- ZHIBQGJKHVBLJJ-UHFFFAOYSA-N histamine phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.NCCC1=CNC=N1 ZHIBQGJKHVBLJJ-UHFFFAOYSA-N 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-N sodium;hydron;carbonate Chemical compound [Na+].OC(O)=O UIIMBOGNXHQVGW-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a kind of gynecopathy treating medicine and its preparation process. The medicine is used for treating women's bacterial vaginitis, trichomonal vaginitis and mycotic vaginitis as common gynecopathy, and is superior to available medicine for the same use. The gynecopathy treating medicine is prepared with gallnut, wild chrysanthemum flower, phellodendron bark, sodium bicarbonate, citric acid and other five kinds of Chinese medicinal materials. It has the functions of clearing away heat, dispersing dampness, killing parasites, stopping itching, dissipating blood stasis, reducing swelling and easing pain. It has the advantages of fast acting, high healing effect, no toxic side effect and low recurrence rate.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of gynaecopathia and preparation method thereof.
Background technology
Bacillary, infusorian property, colpitis mycotica are the inflammation that connective tissue causes under cause of disease infringement vaginal mucosa by direct or indirect contact infection and the mucosa, are common gynecological diseases.Because the management of extensive use of antibiotic, immunosuppressant in recent years and public place, sterilization are not tight, make the sickness rate of above-mentioned vagina increase to some extent.According to relevant: " the present sickness rate of such disease accounts for women crowd's 10%-23%.In the morbidity crowd, bacterial vaginitis accounts for 41%, and trichomonal vaginitis accounts for 24%, and colpitis mycotica accounts for 27%." this is seriously endangering women's physical and mental health, so it is significant to be devoted to treat the research of above-mentioned disease.
" bacterial vaginitis is because ability of Lactobacillus in human vagina reduces, and other antibacterial breeds in a large number, mainly contains Gartner Salmonella, Streptococcus lactis (Lister) Lohnis 1909.554., escherichia coli, Bacillus proteus, reaches the mixed infection that mycoplasma causes." modern medicine is treated it, mainly is metronidazole for oral administration, Clindamicin, ampicillin, and is local with metronidazole, JIEERYIN XIYE." trichomonal vaginitis per vaginam trichomonacide causes, the propagated infectious disease of attribute, and trichomonal vaginitis can consume the vagina epithelium glycogen, makes vaginal wall acidity reduce the easier breeding of infusorian." modern medicine treats it; mainly make metronidazole for oral administration, piperanitrozole, tinidazole; local with ace-tarsoni, carbarsone, hachimycin, metronidazole, at the low acid environment of vagina, with 0.5% acetate solution, 10% lactate buffer solution, washing vagina as complementary therapy." colpitis mycotica is because the intravaginal glycogen of intravaginal dysbacteriosis or diabetes, pregnancy women increases, and ability of Lactobacillus in human vagina is suppressed, and mycete (mainly being Candida albicans) is easy to growth and breeding, causes a disease." modern medicine is treated it, mainly is nystatin for oral administration, ketoconazole, clotrimazole, econazole, hachimycin, imidazole, fluconazol, itraconazole use 2-4% soda solution washing vagina as complementary therapy at the high acid environment of vagina.
Above-mentioned at pathogenic former medicine, its effect of killing bacterium, worm is comparatively remarkable, but certain side effect or toxicity are arranged, and relapse rate is higher after the drug withdrawal.As metronidazole, Clindamicin, ammonia benzyl mycin, piperanitrozole, tinidazole, ace-tarsoni, carbarsone, hachimycin, nystatin, side effect such as that ketoconazole, clotrimazole, econazole, imidazole, fluconazol, itraconazole all have is nauseating, diarrhoea, erythra.Dizzy, insomnia that metronidazole can also cause, idol has leukopenia, or nervus centralis poisoning symptom (as movement disorder)." miconazole class medicine also has certain infringement to liver, renal function.”
Chinese medicine is according to its unique theoretical system and drug resource, and the determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs female vagina is being brought into play important effect always.The critical treatment female vagina is not only evident in efficacy, and non-evident effect.Yet traditional Chinese traditional treatment mainly is with the oral or demibain of Chinese medicine decoction, flushing, and is very inconvenient when the patient uses.
Summary of the invention
The object of the present invention is to provide a kind of medicine for the treatment of gynaecopathia and preparation method thereof.
For achieving the above object, the technical solution used in the present invention is:
A kind of medicine for the treatment of gynaecopathia, it is the medicament that is prepared into by the following weight proportion raw material:
72~88 parts of 90~110 portions of Cortex Phellodendris of 180~220 parts of Flos Chrysanthemi Indicis of Galla Chinensis
16.2~19.8 parts of 36~44 parts of Radix Paeoniae Rubra of 45~55 parts of Fructus Cnidiis of Pericarpium Granati
67.5~82.5 parts of 1.8~2.2 parts of sodium bicarbonate of 9~11 parts of Borneolum Syntheticums of dried Alumen
81~99 parts of citric acid
Above-mentioned a kind of medicine for the treatment of gynaecopathia, wherein the weight proportion of each raw material is:
76~84 parts of 95~105 portions of Cortex Phellodendris of 190~210 parts of Flos Chrysanthemi Indicis of Galla Chinensis
17.1~18.9 parts of 38~42 parts of Radix Paeoniae Rubra of 47.5~52.5 parts of Fructus Cnidiis of Pericarpium Granati
71.25~78.75 parts of 1.9~2.1 parts of sodium bicarbonate of 9.5~10.5 parts of Borneolum Syntheticums of dried Alumen
81~99 parts of citric acid
Above-mentioned a kind of medicine for the treatment of gynaecopathia, wherein the weight proportion of each raw material is:
80 parts of 100 portions of Cortex Phellodendris of 200 parts of Flos Chrysanthemi Indicis of Galla Chinensis
18 parts of 40 parts of Radix Paeoniae Rubra of 50 parts of Fructus Cnidiis of Pericarpium Granati
75 parts of 2 parts of sodium bicarbonate of 10 parts of Borneolum Syntheticums of dried Alumen
90 parts of citric acid
Above-mentioned a kind of medicine for the treatment of gynaecopathia, its dosage form are that the processing step of preparation method of effervescent tablet is as follows:
A. concoct
Galla Chinensis: get crude drug, knock open, remove the debug dirt, impurity is smashed to pieces;
Cortex Phellodendri: remove impurity, the spray clear water runs through shredding, drying;
Pericarpium Granati: remove impurity, remove clean residual interior flesh and seed, smash to pieces after the cleaning, drying;
Radix Paeoniae Rubra: remove impurity, separately size is cleaned, and runs through shave, drying;
Dried Alumen: get clean Alumen, put the marmite internal heating and dissolve, take out, smash to pieces to the cellular blocks of solid of whole formation;
Citric acid: 70-75 ℃ of drying and dehydrating 24 hours, standby with preceding;
All the other each flavors clean standby;
B. pulverize
Alumen powder is broken into fine powder, crosses 100 mesh sieves, and is standby;
Borneolum Syntheticum is pulverized, and crosses 60 mesh sieves, and is standby;
All the other medicated powder of respectively distinguishing the flavor of are broken into the Semen Glycines bulky grain, and are standby;
C. extract, separate with concentrated
(1) gets the Fructus Cnidii medical material and put in the multi-function extractor, add 8 times of 95% alcohol dipping 2 hours, the hot reflux secondary, each 2 hours, filter, medicinal residues stay does decocting use, alcohol extract decompression recycling ethanol, evaporating temperature 50-60 ℃, vacuum 0.08-0.09MPa, heating steam pressure are 0.05-0.09MPa, get the alcohol extract thick paste, yield is about 9.5%, and is standby;
(2) medicinal residues of getting after Flos Chrysanthemi Indici, Cortex Phellodendri medical material and the Fructus Cnidii alcohol extraction are fried in shallow oil three times altogether, and amount of water is respectively 10,8,8 times of medical material, and the time respectively is 1.5 hours.Decoction liquor filters the back and merges, concentrating under reduced pressure, and vacuum 0.06-0.08MPa, evaporating temperature is 60-70 ℃, and heating steam pressure is 0.05-0.08Mpa, and becoming relative density is the thick paste of 1.30-1.35, and it is at 60 ℃, and heat is surveyed down, yield about 25%;
(3) get Galla Chinensis, Pericarpium Granati, Radix Paeoniae Rubra decocting secondary, 2 hours for the first time, 1.5 hours for the second time, amount of water is respectively 10,8 times, after decoction liquor filters, merge concentrating under reduced pressure, vacuum 0.06-0.08MPa, evaporating temperature is 60-70 ℃, heating steam pressure is 0.05-0.08Mpa, and becoming relative density is the thick paste of 1.30-1.35, and it is at 60 ℃, heat is surveyed down, yield about 40%;
D. dry
(1) two thick pastes with (1), (2) gained among the step C mix, and add dry starch in 1: 1 ratio and mix thoroughly, and 60-70 ℃, heating steam pressure is 0.03MPa, vacuum 0.06-0.08Mpa, vacuum drying;
(2) with the thick paste 60-70 ℃ vacuum drying of (3) among a step C gained, heating steam pressure is 0.03MPa, vacuum 0.06-0.08MPa;
E. granulate
(1) dried cream powder with (1) among step D gained is broken into fine powder, crosses 100 mesh sieves, with sodium bicarbonate, and the dried Alumen fine powder, the appropriate amount of starch mixing is mixed thoroughly, with 50% ethanol moistening, makes soft material, and 18 mesh sieves are granulated, 60-65 ℃ of oven dry, standby behind the granulate, this pellet moisture should not be higher than 2%;
(2) dried cream powder with (2) among step D gained is broken into fine powder, crosses 100 mesh sieves, with 95% ethanol moistening, makes soft material, and 18 mesh sieves are granulated, 60-65 ℃ of oven dry, and standby behind the granulate, pellet moisture is not higher than 2%;
(3) citric acid after the dehydration is directly pulverized granulation, crosses 20 mesh sieves, gets final product;
F. three kinds of granules with the step e gained mix, and add Borneolum Syntheticum powder and an amount of Pulvis Talci, mix thoroughly, are pressed into special-shaped tablets, single dose plastic-aluminum cover blister package, promptly.
Medicine of the present invention is with respect to prior art, and its advantage is as follows:
1, have no side effect, easy to use;
2, rapid-action, general 24 hours take effect with interior, improve and to eliminate the symptom effect remarkable;
3, it is stronger to kill the former effect of causing a disease, and the relapse rate after curing is lower;
4, prescription uniqueness, the effect uniqueness possesses double effects, can removing damp-heat, killing parasites for relieving itching, again can the dissipating blood stasis for subsidence of swelling pain relieving.
The specific embodiment
The present invention is a kind of medicine for the treatment of gynaecopathia, and it is by Galla Chinensis, Flos Chrysanthemi Indici, and Cortex Phellodendri, Pericarpium Granati, Fructus Cnidii, Radix Paeoniae Rubra, dried Alumen, Borneolum Syntheticum, sodium bicarbonate, citric acid constitutes,
Main pharmacodynamics of the present invention can be reached a conclusion by following experiment:
One, the present invention is to the killing in vitro and the inhibitory action of trichomonal vaginitis
Set up experiment infusorian matched group (negative control), JIEERYIN XIYE matched group (positive control) and 12.5%, 25.0%, 50.0%, 100% 4 concentration solution experiments group in the experimentation.
Experimental result sees Table 1
Table 1 the present invention is to the average eradicative rate (%) of trichomonal vaginitis
Grouping | 5min | 15min | 30min | 60min | The 72h recovery |
Negative control group 100% dosage 50% dosage 25% dosage 12.5% dosage JIEERYIN group | 0 100 98 90 87 83 | 0 100 100 100 100 91 | 0 100 100 100 100 98 | 0.2 100 100 100 100 100 | The dead polypide death of the survival polypide destruction polypide dead polypide of destruction polypide |
By table 1 as seen, the present invention is external has significant killing action to pathogenic trichomonal vaginitis.The concentration of its minimum infusorian of effectively going out is: 12.5% (15min); The shortest time of killing infusorian is 5min (100% concentration).This medicine obviously is better than JIEERYIN in the effect of killing in vitro trichomonal vaginitis.
Two, the experimental result of the present invention's mice subcutaneous abscess model effect that trichomonal vaginitis is caused
After animal was weighed, normal control group and model control group normal saline, experimental group were used the solution of the present invention of 12.5%, 25.0%, 50.0% 3 concentration respectively, the positive controls JIEERYIN XIYE, smear inoculation position skin, every day twice, successive administration 7 days.Experimental result sees Table 2 and table 3.
Table 2 the present invention is to the unit that influences of experiment mice body weight: g (X ± S)
Grouping | Number of animals | Body weight during grouping (1) | Body weight (2) before putting to death | (2) compare in (1) |
Dosage group small dose group JIEERYIN group in the heavy dose of group of normal group model group | 20 20 20 20 20 20 | 20.1±1.67 20.0±1.92 19.9±1.64 20.0±1.88 20.1±1.50 20.3±2.07 | 21.7±1.64 21.3±1.84 20.6±1.40 20.5±1.39 21.0±1.38 21.7±2.13 | The average 1.6g/ of increasing only the average 1.3g/ of increasing only the average 0.7g/ of increasing only the average 0.5g/ of increasing only the average 0.9g/ of increasing is only average only increases 1.4g/ |
Table 3 the present invention is to the influence of model mice subcutaneous abscess
Group | Number of animals | The recovery from illness number | Cure rate (%) |
The low dose of administration group of dosed administration group JIEERYIN administration group in the heavy dose of administration group of normal control group model matched group | 20 20 20 20 20 20 | - 3 5 9 20 4 | - 15 25 45 100 20 |
Under the normal raising condition, all animal body weight averages increase gradually, and with after the administration of the present invention, the increase of body weight seemingly has the trend that slows down.The present invention is inhibited in the mice subcutaneous abscess that trichomonal vaginitis is caused, during its administration concentration 12.5%, the abscess of all laboratory animals is disappeared, but along with the increase of dosage, its inhibitory action to abscess weakens.Experimental result confirms that also the inhibition of the mice subcutaneous abscess that solution of the present invention causes trichomonal vaginitis is all obvious than JIEERYIN.
Three, the present invention's rabbit experiment bacterial vaginitis effect experimental result that mixed cell is caused
After animal was weighed, normal control group and model control group normal saline, experimental group were used five times of solution of the present invention of 12.5%, 25.0%, 50.0% 3 concentration respectively, the positive controls JIEERYIN XIYE, lavation laboratory animal vagina, every day twice, successive administration 7 days.Experimental result sees Table 4 and table 5.
Table 4 the present invention is to the unit that influences of experimental rabbit body weight: kg (X ± S)
Grouping | Number of animals | Body weight during grouping (1) | Body weight behind the model (2) | Body weight (3) before putting to death | (2) compare with (1) | (3) compare with (2) |
Dosage group small dose group JIEERYIN group in the heavy dose of group of normal group model group | 6 6 6 6 6 6 | 2.079±0.352 2.087±0.154 2.197±0.392 2.056±0.343 2.595±0.323 2.198±0.289 | 2.095±0.325 2.047±0.216 1.911±0.401 1.815±0.310 2.112±0.354 2.010±0.245 | 2.131±0.286 1.963±0.259 2.065±0.344 1.914±0.319 2.240±0.382 1.913±0.237 | Once added 0.016 and reduced by 0.040 reduction, 0.286 reduction, 0.241 reduction, 0.483 reduction by 0.188 | Increase by 0.036 reduction, 0.084 increase, 0.154 increase, 0.099 increase by 0.128 and reduce by 0.285 |
Table 5 the present invention is to the therapeutical effect of rabbit bacterial vaginitis
Group | Number of animals | Recovery from illness number (rate %) | Good revolution (rate %) | Effective percentage (%) |
Dosage group small dose group JIEERYIN group in the heavy dose of group of normal group model group | 6 6 6 6 6 6 | - 0 6(100) 6(100) 5(83.3) 4(66.7) | - 0 0 0 1(16.7) 1(16.7) | - 0 6(100) 6(100) 6(100) 5(83.3) |
Under the normal raising condition, the rabbit body weight increases gradually, and behind the bacterial infection, body weight obviously descends, and with after the Drug therapy of the present invention, body weight all begins to increase, and JIEERYIN group body weight does not increase.By the treatment experiment confirm, medicine of the present invention has the obvious treatment effect to the rabbit bacterial vaginitis, its administration concentration promptly had the obvious treatment effect at 12.5% o'clock, can see significantly that by the pathological examination result its restitution to bacterial infection is better than JIEERYIN.
Four, the experiment of the present invention's rabbit experiment colpitis mycotica therapeutical effect that Candida albicans is caused
After animal was weighed, normal control group and model control group normal saline, experimental group were used the solution of the present invention of 12.5%, 25.0%, 50.0% 3 concentration respectively, the positive controls JIEERYIN XIYE, lavation laboratory animal vagina, every day twice, successive administration 7 days.Experimental result sees Table 6 and table 7.
Table 6 the present invention is to the unit that influences of experimental rabbit body weight: kg (X ± S)
Grouping | Number of animals | Body weight during grouping (1) | Body weight behind the model (2) | Body weight (3) before putting to death | (2) compare with (1) | (3) compare with (2) |
Dosage group small dose group JIEERYIN group in the heavy dose of group of normal group model group | 6 6 6 6 6 6 | 1.973±0.202 1.857±0.200 1.874±0.304 2.000±0.259 1.722±0.187 2.104±0.234 | 2.012±0.200 1.785±0.196 1.811±0.268 1.990±0.260 1.786±0.192 2.140±0.189 | 2.087±0.173 1.685±0.169 1.677±0.262 1.827±0.283 1.623±0.214 1.964±0.173 | Increase by 0.039 reduction, 0.072 reduction, 0.063 reduction, 0.163 increase by 0.064 and increase by 0.036 | Increase by 0.075 increase, 0.100 reduction, 0.134 increase, 0.075 reduction by 0.163 and reduce by 0.176 |
Table 7 the present invention is to the therapeutical effect of rabbit colpitis mycotica
Group | Number of animals | Recovery from illness number (rate %) | Good revolution (rate %) | Effective percentage (%) |
Dosage group small dose group JIEERYIN group in the heavy dose of group of normal group model group | 6 6 6 6 6 6 | - 0 5(83.3) 4(66.7) 4(66.7) 5(83.3) | - 0 1(16.7) 2(33.3) 1(16.7) 1(16.7) | - 0 6(100) 6(100) 5(83.3) 6(100) |
Under the normal raising condition, except that normal control group rabbit body weight increased gradually, behind the infection Candida albicans, body weight slightly descended, and with after the Drug therapy of the present invention, body weight all continues to reduce.By the treatment experiment confirm, medicine of the present invention has the obvious treatment effect to the rabbit colpitis mycotica, its administration concentration promptly had the obvious treatment effect at 12.5% o'clock, can see significantly that by the pathological examination result its restitution to fungal infection is better than JIEERYIN.
Other drug effects of the present invention also can draw by experiment to draw a conclusion:
The rat paw edema that on Carrageenan of the present invention, Ovum Gallus domesticus album cause has antagonism, can alleviate the mice auricle swelling that dimethylbenzene causes, can alleviate rat agar granuloma weight, and showing has antiinflammatory action; Mice there is analgesic activity with the evidence that hot plate method and writhing method carry out; Have and improve the Cavia porcellus itch-threshold effect that histamine phosphate causes, showing has itching-relieving action; Can significantly expand the effect of mice arteriole caliber, show the effect that microcirculation improvement is arranged.
The present invention has also carried out long-term toxicity test for animals, does not see that outward appearance, body weight gain appear in animal, and the toxicity of hemogram, liver, renal function and 17 kinds of organs and tissues changes, and drug withdrawal recovers not see in 3 weeks that delayed toxicity takes place; Carried out animal acute toxicity test, the animals administer amount is equivalent to Coming-of-Age Day 180 times with dosage, does not cause animal dead; Carried out the local skin irritant test, breakage all has no stimulation to the Cavia porcellus complete sum; Carried out skin anaphylactic test, do not seen that skin has anaphylaxis.
For showing that medicine of the present invention to colpitic therapeutic effect, the invention provides the data of one group of clinical test results.Year November in October, 1999 to 1999, by the clinical staff of Shaanxi Chinese medicine academy Affiliated Hospital, (product batch number: 19990824) 50 examples (30 days courses of treatment) clinical preliminary test has been carried out in the curative effect and the safety that belong to traditional Chinese medical science syndrome of dampness-heat diffusing downward of bacillary, the infusorian property of treatment, colpitis mycotica to the effervescent tablet of the present invention of centering trial production.Result: bacterial vaginitis (14 example) recovery from illness 9 examples, produce effects 2 examples, effective 2 examples, invalid 1 example, trichomonal vaginitis (18 example) recovery from illness 5 examples, produce effects 7 examples, effective 5 examples, invalid 1 example, colpitis mycotica (18 example) recovery from illness 8 examples, produce effects 6 examples, effective 4 examples, invalid 0 example.Total obvious effective rate 74%, total effective rate 96%.Trial test is the result show: this medical instrument has rapid-action (in general 24 hours), improvement and elimination symptom effect are remarkable, it is stronger to kill the former effect of causing a disease, and lower (trichomonal vaginitis 1 example that clinical cure is only arranged of relapse rate after curing, 3 menstrual cycle are followed up a case by regular visits to after the drug withdrawal, recurrence is arranged, so the produce effects of being judged to be).
Embodiment 1:
The invention provides a kind of medicine for the treatment of gynaecopathia, the weight proportion of its each raw material is:
Galla Chinensis 200g Flos Chrysanthemi Indici 100g Cortex Phellodendri 80g
Pericarpium Granati 50g Fructus Cnidii 40g Radix Paeoniae Rubra 18g
Dried Alumen 10g Borneolum Syntheticum 2g sodium bicarbonate 75g
Citric acid 90g
The processing step of the preparation method of its effervescent tablet is as follows:
A. concoct
Galla Chinensis: get crude drug, knock open, remove the debug dirt, impurity is smashed to pieces;
Cortex Phellodendri: remove impurity, the spray clear water runs through shredding, drying;
Pericarpium Granati: remove impurity, remove clean residual interior flesh and seed, smash to pieces after the cleaning, drying;
Radix Paeoniae Rubra: remove impurity, separately size is cleaned, and runs through shave, drying;
Dried Alumen: get clean Alumen, put the marmite internal heating and dissolve, take out, smash to pieces to the cellular blocks of solid of whole formation;
Citric acid: 70-75 ℃ of drying and dehydrating 24 hours, standby with preceding;
All the other each flavors clean standby.
B. pulverize
Alumen powder is broken into fine powder, crosses 100 mesh sieves, and is standby;
Borneolum Syntheticum is pulverized, and crosses 60 mesh sieves, and is standby;
All the other medicated powder of respectively distinguishing the flavor of are broken into the Semen Glycines bulky grain, and are standby.
C. extract, separate with concentrated
(1) getting the Fructus Cnidii medical material puts in the multi-function extractor, add 8 times of 95% alcohol dipping 2 hours, hot reflux secondary, each 2 hours, filter, medicinal residues stay does decocting use, alcohol extract decompression recycling ethanol, evaporating temperature 50-60 ℃, vacuum 0.08-0.09MPa, heating steam pressure is 0.05-0.09MPa, gets alcohol extract thick paste (yield about 9.5%), and is standby;
(2) medicinal residues of getting after Flos Chrysanthemi Indici, Cortex Phellodendri medical material and the Fructus Cnidii alcohol extraction are fried in shallow oil three times altogether, and amount of water is respectively 10,8,8 times of medical material, and the time respectively is 1.5 hours.Decoction liquor filters the back and merges, and concentrating under reduced pressure (vacuum 0.06-0.08MPa, evaporating temperature is 60-70 ℃, heating steam pressure is 0.05-0.08MPa) one-tenths relative density is the thick paste (yield about 25%) of 1.30-1.35 (60 ℃, the heat survey);
(3) get Galla Chinensis, Pericarpium Granati, Radix Paeoniae Rubra decocting secondary, 2 hours for the first time, 1.5 hours for the second time, amount of water is respectively 10,8 times, after decoction liquor filters, and the merging concentrating under reduced pressure (vacuum 0.06-0.08MPa, evaporating temperature is 60-70 ℃, heating steam pressure is 0.05-0.08MPa) the one-tenth relative density is the thick paste (yield about 40%) of 1.30-1.35 (60 ℃, heat survey);
D. dry
(1) two thick pastes with (1), (2) gained among the step C mix, and add dry starch in 1: 1 ratio and mix 60-70 ℃ of (heating steam pressure is 0.03MPa, vacuum 0.06-0.08MPa) vacuum drying thoroughly;
(2) with the thick paste 60-70 ℃ vacuum drying (heating steam pressure is 0.03MPa, vacuum 0.06-0.08MPa) of (3) gained among the step C.
E. granulate
(1) dried cream powder with (1) among step D gained is broken into fine powder (crossing 100 mesh sieves) and sodium bicarbonate, the dried Alumen fine powder, and the appropriate amount of starch mixing is mixed thoroughly, with 50% ethanol moistening, make soft material, 18 mesh sieves are granulated, 60-65 ℃ of oven dry, standby behind the granulate, this pellet moisture should not be higher than 2%;
(2) dried cream powder with (2) among step D gained is broken into fine powder (crossing 100 mesh sieves), with 95% ethanol moistening, makes soft material, and 18 mesh sieves are granulated, 60-65 ℃ of oven dry, and standby behind the granulate, pellet moisture is not higher than 2%.
(3) citric acid after the dehydration is directly pulverized granulation, crosses 20 mesh sieves, gets final product.F. three kinds of granules with the step e gained mix, and add Borneolum Syntheticum powder and an amount of Pulvis Talci, mix thoroughly, are pressed into special-shaped tablets, and single dose plastic-aluminum cover blister package get final product.
Using method:
External behind the clean vagina, is sent 2 tablets of medicines into the vagina deep, and is clogged vaginal orifice with aseptic cotton balls before sleeping every day 1 time, in case the medicinal liquid outflow affects the treatment and pollution clothes.
Embodiment 2:
The invention provides a kind of medicine for the treatment of gynaecopathia, the weight proportion of its each raw material is:
Galla Chinensis 180g Flos Chrysanthemi Indici 90g Cortex Phellodendri 72g
Pericarpium Granati 45g Fructus Cnidii 36g Radix Paeoniae Rubra 16.2g
Dried Alumen 9g Borneolum Syntheticum 1.8g sodium bicarbonate 67.5g
Citric acid 81g
Its preparation method is identical with embodiment 1;
Embodiment 3:
The invention provides a kind of medicine for the treatment of gynaecopathia, the weight proportion of its each raw material is:
Galla Chinensis 220g Flos Chrysanthemi Indici 110g Cortex Phellodendri 88g
Pericarpium Granati 55g Fructus Cnidii 44g Radix Paeoniae Rubra 19.8g
Dried Alumen 11g Borneolum Syntheticum 2.2g sodium bicarbonate 82.5g
Citric acid 99g
Its preparation method is identical with embodiment 1.
Claims (4)
1, a kind of medicine for the treatment of gynaecopathia is characterized in that it is the medicament that is prepared into by the following weight proportion raw material:
72~88 parts of 90~110 portions of Cortex Phellodendris of 180~220 parts of Flos Chrysanthemi Indicis of Galla Chinensis
16.2~19.8 parts of 36~44 parts of Radix Paeoniae Rubra of 45~55 parts of Fructus Cnidiis of Pericarpium Granati
67.5~82.5 parts of 1.8~2.2 parts of sodium bicarbonate of 9~11 parts of Borneolum Syntheticums of dried Alumen
81~99 parts of citric acid.
2, a kind of medicine for the treatment of gynaecopathia as claimed in claim 1 is characterized in that wherein the weight proportion of each raw material is:
76~84 parts of 95~105 portions of Cortex Phellodendris of 190~210 parts of Flos Chrysanthemi Indicis of Galla Chinensis
17.1~18.9 parts of 38~42 parts of Radix Paeoniae Rubra of 47.5~52.5 parts of Fructus Cnidiis of Pericarpium Granati
71.25~78.75 parts of 1.9~2.1 parts of sodium bicarbonate of 9.5~10.5 parts of Borneolum Syntheticums of dried Alumen
81~99 parts of citric acid.
3, a kind of medicine for the treatment of gynaecopathia as claimed in claim 1 is characterized in that wherein the weight proportion of each raw material is:
80 parts of 100 portions of Cortex Phellodendris of 200 parts of Flos Chrysanthemi Indicis of Galla Chinensis
18 parts of 40 parts of Radix Paeoniae Rubra of 50 parts of Fructus Cnidiis of Pericarpium Granati
75 parts of 2 parts of sodium bicarbonate of 10 parts of Borneolum Syntheticums of dried Alumen
90 parts of citric acid.
4, according to claim 1,2 or 3 described a kind of medicines for the treatment of gynaecopathia, it is characterized in that: described dosage form is that the processing step of preparation method of effervescent tablet is as follows:
A. concoct
Galla Chinensis: get crude drug, knock open, remove the debug dirt, impurity is smashed to pieces;
Cortex Phellodendri: remove impurity, the spray clear water runs through shredding, drying;
Pericarpium Granati: remove impurity, remove clean residual interior flesh and seed, smash to pieces after the cleaning, drying;
Radix Paeoniae Rubra: remove impurity, separately size is cleaned, and runs through shave, drying;
Dried Alumen: get clean Alumen, put the marmite internal heating and dissolve, take out, smash to pieces to the cellular blocks of solid of whole formation;
Citric acid: 70-75 ℃ of drying and dehydrating 24 hours, standby with preceding;
All the other each flavors clean standby;
B. pulverize
Alumen powder is broken into fine powder, crosses 100 mesh sieves, and is standby;
Borneolum Syntheticum is pulverized, and crosses 60 mesh sieves, and is standby;
All the other medicated powder of respectively distinguishing the flavor of are broken into the Semen Glycines bulky grain, and are standby;
C. extract, separate with concentrated
(1) gets the Fructus Cnidii medical material and put in the multi-function extractor, add 8 times of 95% alcohol dipping 2 hours, the hot reflux secondary, each 2 hours, filter, medicinal residues stay does decocting use, alcohol extract decompression recycling ethanol, evaporating temperature 50-60 ℃, vacuum 0.08-0.09MPa, heating steam pressure are 0.05-0.09MPa, get the alcohol extract thick paste, yield is about 9.5%, and is standby;
(2) medicinal residues of getting after Flos Chrysanthemi Indici, Cortex Phellodendri medical material and the Fructus Cnidii alcohol extraction are fried in shallow oil three times altogether, and amount of water is respectively 10,8,8 times of medical material, and the time respectively is 1.5 hours.Decoction liquor filters the back and merges, concentrating under reduced pressure, and vacuum 0.06-0.08MPa, evaporating temperature is 60-70 ℃, and heating steam pressure is 0.05-0.08Mpa, and becoming relative density is the thick paste of 1.30-1.35, and it is at 60 ℃, and heat is surveyed down, yield about 25%;
(3) get Galla Chinensis, Pericarpium Granati, Radix Paeoniae Rubra decocting secondary, 2 hours for the first time, 1.5 hours for the second time, amount of water is respectively 10,8 times, after decoction liquor filters, merge concentrating under reduced pressure, vacuum 0.06-0.08MPa, evaporating temperature is 60-70 ℃, heating steam pressure is 0.05-0.08Mpa, and becoming relative density is the thick paste of 1.30-1.35, and it is at 60 ℃, heat is surveyed down, yield about 40%;
D. dry
(1) two thick pastes with (1), (2) gained among the step C mix, and add dry starch in 1: 1 ratio and mix thoroughly, and 60-70 ℃, heating steam pressure is 0.03MPa, vacuum 0.06-0.08Mpa, vacuum drying;
(2) with the thick paste 60-70 ℃ vacuum drying of (3) among a step C gained, heating steam pressure is 0.03MPa, vacuum 0.06-0.08MPa;
E. granulate
(1) dried cream powder with (1) among step D gained is broken into fine powder, crosses 100 mesh sieves, with sodium bicarbonate, and the dried Alumen fine powder, the appropriate amount of starch mixing is mixed thoroughly, with 50% ethanol moistening, makes soft material, and 18 mesh sieves are granulated, 60-65 ℃ of oven dry, standby behind the granulate, this pellet moisture should not be higher than 2%;
(2) dried cream powder with (2) among step D gained is broken into fine powder, crosses 100 mesh sieves, with 95% ethanol moistening, makes soft material, and 18 mesh sieves are granulated, 60-65 ℃ of oven dry, and standby behind the granulate, pellet moisture is not higher than 2%;
(3) citric acid after the dehydration is directly pulverized granulation, crosses 20 mesh sieves, gets final product;
F. three kinds of granules with the step e gained mix, and add Borneolum Syntheticum powder and an amount of Pulvis Talci, mix thoroughly, are pressed into special-shaped tablets, single dose plastic-aluminum cover blister package, promptly.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100419383A CN100384447C (en) | 2006-03-15 | 2006-03-15 | Medicine for treating gynecopathy and its preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100419383A CN100384447C (en) | 2006-03-15 | 2006-03-15 | Medicine for treating gynecopathy and its preparing method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1857498A true CN1857498A (en) | 2006-11-08 |
CN100384447C CN100384447C (en) | 2008-04-30 |
Family
ID=37296486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100419383A Active CN100384447C (en) | 2006-03-15 | 2006-03-15 | Medicine for treating gynecopathy and its preparing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100384447C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014059880A1 (en) * | 2012-10-18 | 2014-04-24 | 中国科学院新疆理化技术研究所 | Method for preparation of pomegranate-peel polyphenol gel used to treat gynecological inflammation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1097604A (en) * | 1993-07-21 | 1995-01-25 | 黄勇 | Fumigating and washing hemorrhoid curing powder and preparation method thereof |
-
2006
- 2006-03-15 CN CNB2006100419383A patent/CN100384447C/en active Active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014059880A1 (en) * | 2012-10-18 | 2014-04-24 | 中国科学院新疆理化技术研究所 | Method for preparation of pomegranate-peel polyphenol gel used to treat gynecological inflammation |
EA029649B1 (en) * | 2012-10-18 | 2018-04-30 | Синьцзян Текникал Инститьют Оф Физикс Энд Кемистри, Чайниз Экэдеми Оф Сайенсиз | Pomegranate-peel polyphenol gel used to treat gynecological inflammation diseases and method for preparation thereof |
Also Published As
Publication number | Publication date |
---|---|
CN100384447C (en) | 2008-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1768812A (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
CN106361830B (en) | Rhubarb powder and preparation method thereof | |
CN1824101A (en) | Xingsuerchen medicinal preparation and its new preparation method | |
CN102018754B (en) | Vaginal effervescent tablet and making process thereof | |
CN1927279A (en) | Chinese medicine composition for treating skin disease | |
CN1857498A (en) | Medicine for treating gynecopathy and its preparing method | |
CN1293913C (en) | Chinese medicinal tea bag for treating acute and chronic pharyngitis and its production method | |
CN1879701A (en) | Cold-treating medicine and preparation method thereof | |
CN103520330B (en) | A kind of veterinary dispersible tablet and its production and use | |
CN1298351C (en) | Chinese medicine oral preparaton for treating urinary system infestation and its preparation method | |
CN1215595A (en) | External use medicine for treating soft tissue injury and its producing method | |
CN1278709C (en) | Medicine for treating cold and its preparing process | |
CN1191849C (en) | Chinese medicine for treating breast disease | |
CN1931279A (en) | Medicine for treating biliary tract infection and its prepn process | |
CN1899392A (en) | Chinese medicine composition for treating gynecological inflammation and its preparing method and use | |
CN1824099A (en) | Diffusing-freeing lung rectifying medicinal preparation and its new preparation method | |
CN1857492A (en) | Qingxie preparation and its preparing process | |
CN1772239A (en) | Chinese medicine prepn for treating vaginitis and cervicitis | |
CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method | |
CN1265810C (en) | A pharmaceutical composition for treating cyclomastopathy, and its preparation method | |
CN1634296A (en) | Medicine for treating male infertility | |
CN1943701A (en) | A kind of medicine for treatment of non-gonococcal urethritis(NGU) and its preparation method | |
CN1205975C (en) | Chinese medicine for treating prostatitis | |
CN101032572A (en) | Sanguisorba huaijiao agent and the novel preparing method | |
CN1424104A (en) | Medicines for treating chronic prostatitis and preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160901 Address after: 716000 Yanan province Shaanxi City Baota District Chang Road No. 88 Chang Taiyuan Patentee after: Yanan pharmaceutical Limited by Share Ltd Address before: 716000 Shaanxi city of Yanan province Chang Tai Road No. 88 Chang Taiyuan Patentee before: Chang Xuejun |